Improving target volume delineation for 3D image-based dosimetry in PRRT

Author(s): Dr Emiliano Spezi, Dr Salvatore Berenato

Hospital: Cardiff University, Velindre Cancer Centre

Reference: RAD Magazine, 47, 556, 21-26


Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is currently the most effective molecular radiotherapy (MRT) treatment for patients who suffer from neuroendocrine tumours (NET) with metastasised disease. In PRRT the treatment is systemic and the most frequent treatment protocol is to administer 7.4GBq of Lu-177 up to four times with a six to 10-week interval between each administration. The cumulative absorbed dose that can be administered to the tumour is limited by the unavoidable irradiation of the organs at risk (OAR), such as kidneys and bone marrow.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more